Compare Booz Allen Hamilton Holding Corporation (BAH) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Citius Pharmaceuticals Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $77.73 (market cap $9.45B), while Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 472.3× Citius Pharmaceuticals Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BAH | CTXR | |
|---|---|---|
Market Cap | $9.45B | $20.01M |
Sector | Industrials | Health |
52-Week High | $111.63 | $1.82 |
52-Week Low | $59.71 | $0.48 |
Enterprise Value | $13.07B | $16.23M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.9, up 2.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 7.01% net margin and 68.11% ROE, supported by $11.98B revenue in 2025. Analysts maintain a Buy consensus with a $84.67 price target, citing government contracts and AI investments as growth drivers, though debt levels and civil revenue weakness pose concerns.
The outlook for BAH is positive due to consistent earnings outperformance and strategic focus on national security and cybersecurity. Investment appeal lies in its discounted valuation (P/E 12.33) and dividend yield, but risks include high leverage (debt-to-asset 54.67%) and reliance on government spending, which could impact growth if budget pressures arise.
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
